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In the current issue of Value In Health, Weinstein
and colleagues provide an excellent overview of
mathematical models and their use in policy deci-
sions [1]. Some relevant collateral examples are
provided in environment protection policies, de-
fense strategy, and health care. Key observations
drawn from these examples are used to support an
analytic framework for evaluating models and
their use under Section 114 of the Food and Drug
Administration Modernization Act.
The need for models to inform health-care deci-
sions is compelling. Most interesting is the concept
of “value of information.” It may be too costly to
wait for years expecting long-term data to validate
a model of economic value in health care. A key
issue concerns the nature of the information that
is needed to inform the decision, which is funda-
mentally related to its value.
These observations are especially relevant to
emerging health-care technologies. A hot topic
in some areas is the need for data from large,
lengthy “real-world” studies before new products
are adopted. The hope is that these ambitious studies
could provide definitive evidence of economic value
and bridge the gap between clinical trials and every-
day care. But the interest in this work should be tem-
pered by attention to the immediate needs of patients
and the potential consequences of delaying decisions.
Another theme is the manner in which models
are used and presented. Models are inherently lim-
ited in their ability to predict the future, but they
can still be helpful. Certainly by organizing infor-
mation, bringing to light key assumptions, and pro-
viding rigor to the review of a new technology, a
model can be very useful. So perhaps some models
could be presented to formulary committees as long
as they are presented in a responsible fashion, with
clearly stated assumptions, and cautious or condi-
tional statements instead of inappropriate claims.
In light of these observations, is Section 114 of
the Food and Drug Administration too restrictive?
It is not entirely clear. We still need more experi-
ence in seeing how its application evolves to un-
derstand its full implication.
A key concern about Section 114 is its require-
ment that economic information relate directly to
approved indications. In the case of a medication
indicated for the prevention of myocardial infarc-
tion and stroke, will a model that projects life
years saved based on the survival impact of these
clinical events be interpreted as relating “directly”
to an approved indication? Actions by the FDA to
date suggest that projection of life years gained
from event-level evidence is acceptable.
Under Section 114, a projection of life years saved
for a product indicated only to lower cholesterol may
not be appropriate. However, the regulation might
already allow for presentation of a cholesterol-to-life-
expectancy model, provided that it does not incor-
porate the product being reviewed by the formulary
committee. That is certainly one way to envision a
nonpredictive use: the model is presented to under-
stand the overall costs and consequences of hyper-
cholesterolemia, without new products plugged in.
Finally, the role of Section 114 should be con-
sidered in terms of formulary committee demands.
Right now, some of these committees seem more
interested in simple and straightforward informa-
tion, often well within indicated uses. They may
approach complex models and end points like qual-
ity-adjusted life years with skepticism. Their demand
for information will change as they gain more expe-
rience.
The proposals raised by Weinstein and col-
leagues have a lot of merit. The “value of informa-
tion” needs to be considered when we interpret the
role of mathematical models. The examples from
other areas, such as environmental policy, are ex-
tremely informative. With respect to Section 114,
we need to see how its implementation evolves over
time.
 
References
 
1 Weinstein MC, Toy EL, Sandberg EA, et al. Mod-
eling for health care and other policy decisions:
uses, roles, and validity. Value Health 2001;4:(5).
